Products for Research Use Only

PI3Kδ-IN-25

CAT: 0804-HY-175369Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-175369Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PI3Kδ-IN-25 is an orally active selective PI3Kδ inhibitor (IC50 = 2.1 nM) . PI3Kδ-IN-25 has IC50s of 272, 285, and 1171 nM for PI3Kα, PI3Kγ, and PI3Kβ, respectively. PI3Kδ-IN-25 inhibits AKT Ser473 phosphorylation, suppresses Treg cell proliferation, and downregulates PD-L1 expression in B16F10 cells. PI3Kδ-IN-25 exhibits anticancer effects in B16F10 melanoma and Lewis lung cancer mouse models by reducing tumor-infiltrating Treg cells and enhancing immune responses. PI3Kδ-IN-25 is potentially useful in the study of melanoma, lung cancer, and other cancers[1].
UNSPSC
12352005
Target
Akt; CD3; Interleukin Related; PD-1/PD-L1; PI3K
Related Pathways
Immunology/Inflammation; PI3K/Akt/mTOR
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Smiles
O=C(N1CC[C@H](NC2=NC=NC3=C2C=C(C4=CC(NS(C5=CC=C(C=C5)C)(=O)=O)=C(N=C4)OC)S3)C1)CC
Molecular Formula
C26H28N6O4S2
Molecular Weight
552.67
References & Citations
[1]Lin S, et al. Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for Cancer Immunotherapy. J Med Chem. 2025 Jul 24;68 (14) :14859-14881.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PI3Kδ